Startseite Kongressberichte & Archiv Archiv 2019 ESMO World Congress on Gastrointestinal Cancer Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2

Session XI: Presentation of Selected Abstracts: Colorectal Cancer - Part 2

O-016: Serial assessment of cell-free circulating tumor DNA (ctDNA) to assess treatment effect and minimal residual disease during neoadjuvant and adjuvant therapy in colorectal cancer
Aparna Parikh, et al.

The conclusion from authors abstract:

In this cohort of patients with CRC undergoing neoadjuvant therapy and surgery, patients with persistent ctDNA following completion of surgery or adjuvant therapy were significantly more likely to experience disease recurrence in a shorter period of time. Serial ctDNA assessment following each therapeutic intervention identifies patients with MRD. Understanding dynamic changes in ctDNA detected/not detected status following each clinical intervention can identify patients who may benefit from additional therapies. Prospective interventional studies are ongoing to explore utilizing ctDNA to inform the decision of additional therapies.

O-017: SUNRISE-DI Study: Decision Impact of the 12-Gene Recurrence Score (12-RS) Assay on Adjuvant Chemotherapy Recommendation for Stage II and IIIA/B Colon Cancer (CC)
Jun Watanabe, et al.

The conclusion from authors abstract: 

This is the first study to evaluate the impact of the 12-RS assay on adjuvant treatment recommendations for stage III CC. The 12-RS results significantly influenced treatment decisions for stage II/III patients and their physicians. The decisions were affected in nearly half of stage III and one-third of stage II patients, respectively.

O-018: Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population-based study
Alwers Elizabeth, et al.

The conclusion from authors abstract:

In this population-based study including stage II and III colon cancer patients, we observed a survival benefit of adjuvant chemotherapy for both MSS and MSI-high tumors. Adjuvant chemotherapy seemed to be beneficial among high-risk stage II patients with MSI-high tumors. Our analyses reflect the real-world effectiveness based on observed treatment patterns in an unselected cohort of patients over time.


O-019: Comprehensive Genomic Profiling (CGP) Defines the Genomic Landscape of Colorectal Cancer (CRC) in Individuals of African Ancestry
Parvathi Myer, et al.

The conclusion from authors abstract: 

This is the single largest series of CRC patients reviewed for the differences in genomic profiles within the context of ancestry. Additional independent work is needed to fully confirm the genomic results. However, given the small magnitude of these ancestry-specific differences (<10% at most, typically less), this strongly suggests that disparities in outcome for AFR CRC patients are driven by factors other than intrinsic genomic differences.

O-020: Copy number variation in longitudinal liver metastases biopsies in colorectal cancer identifies biomarker candidates of resistance to standard chemotherapy
Karen Gambaro, et al.

The conclusion from authors abstract:

Our effort to collect and profile next-generation biospecimens provided global genomic and transcriptomic data of the largest LM cohort to date. By analyzing the association between molecular aberrations and patient outcomes, we identified novel biomarker candidates predictive of drug response in LM samples, supporting the utility of collecting metastatic samples in clinical settings.